ORTEXORTEX News
Tracking MTSI? Get live short interest, options flow, and signals on ORTEX.Sign up free →
MT
Earnings PreviewMTSI

MACOM Trails Peers Into Earnings as Analysts Upgrade Into the Dip

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 3 Nov 2026, 05:07

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

MACOM Technology Solutions has fallen harder than its semiconductor peers over the past week, down 8.8% against a median decline of 4.3% for its closest correlated group, which includes Semtech, SiTime, and Teradyne.

That divergence is the sharpest near-term fact about MTSI heading into Wednesday's print. Short interest, at 3.8% of the free float, tells a relatively relaxed story: shorts actually trimmed positions by 9% over the week, and the borrow market is essentially frictionless, with availability at more than 6,000% of short interest and cost to borrow below 0.35%. The squeeze dynamic is absent. Options positioning has shifted toward calls rather than puts: the put/call ratio dropped to 0.52, nearly two standard deviations below its 20-day average of 0.58, suggesting that options traders are expressing more optimism than usual even as the stock price retreats. The stock closed at $222.18 on Monday, down 31% from a month ago.

The most notable institutional signal is the upgrade from Raymond James analyst Melissa Fairbanks last week, who moved to Outperform from Market Perform with a $300 target. That is the most recent action and it runs against the price decline, a deliberate call to buy weakness. BMO Capital made a similar move in September. The broader analyst panel skews positive: four Outperform ratings, two Holds, and a consensus target near $385, which is 73% above Monday's close. The bull case rests on data center optical demand, with 800G and 1.6T products ramping and a book-to-bill of 1.6:1 reported last quarter, alongside expanding defense and LEO satellite revenue and gross margins near 60%. Bears point to execution risk on new products, margin vulnerability from fabrication yields, and pricing pressure from Broadcom, Analog Devices, and Qorvo. The 90-day EPS momentum factor ranks in the 94th percentile, but the forward earnings yield ranks in the 46th, reflecting a valuation that was stretched even before this month's selloff. The PE multiple has compressed by roughly 10 points over 30 days as the price fell.

Insider activity over the past two weeks is mechanically driven rather than discretionary. The recent transactions from the CEO, CFO, COO, and general counsel on October 28 were all coded as tax withholding events on vested shares, not open-market sales. The CFO did execute one open-market sale of 1,027 shares on October 26 under a pre-arranged 10b5-1 plan. Pre-planned sales carry limited signalling value. Net insider activity over 90 days amounts to a modest net reduction of around 9,300 shares. On the institutional side, FMR (Fidelity) remains the largest holder at 13.7%, and BlackRock added roughly 947,000 shares in the most recent quarter. Wikipedia attention for MTSI is running well above its own 90-day average, a z-score near 2.0, consistent with the stock attracting elevated retail interest as the price pulls back sharply.

Retail attention and upgraded analyst coverage are pointing in one direction while the price is moving in the other: the November 5 print will test whether MACOM's operational momentum, particularly the revenue trajectory and gross margin guidance, is enough to close that gap.

Stocks in this article

See the live data behind this article on ORTEX.

Open MTSI on ORTEX →

How this article was generated

Generated
3 Nov 2026, 06:01
Data as of
3 Nov 2026, 05:07
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.